Drugs Xagena

Xagena Mappa
Medical Meeting

Search results for "Cosentyx"

The European Commission ( EC ) has approved Cosentyx ( Secukinumab ) as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Cos ...

The Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Cosentyx ( Secukinumab ) in Europe to treat ankylosing spondylitis ( AS ) and psoriatic arthritis ( PsA ) pa ...

The FDA ( US Food and Drug Administration ) has approved Cosentyx ( Secukinumab ) for the treatment of active non-radiographic axial spondyloarthritis ( nr-axSpA ), confirming Cosentyx efficacy in add ...